See more : JCDecaux SE (JCDXF) Income Statement Analysis – Financial Results
Complete financial analysis of Organicell Regenerative Medicine, Inc. (OCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Organicell Regenerative Medicine, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Americas Gold and Silver Corporation (USAS) Income Statement Analysis – Financial Results
- BeNext-Yumeshin Group Co. (2154.T) Income Statement Analysis – Financial Results
- Archer Materials Limited (ARRXF) Income Statement Analysis – Financial Results
- Domain Holdings Australia Limited (DHG.AX) Income Statement Analysis – Financial Results
- Alabama Power Company (APRDN) Income Statement Analysis – Financial Results
Organicell Regenerative Medicine, Inc. (OCEL)
About Organicell Regenerative Medicine, Inc.
Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.56M | 6.49M | 5.60M | 3.06M | 1.70M | 964.53K | 569.85K | 184.88K | 147.63K | 49.20K | 82.97K | 87.15K | 18.08K |
| Cost of Revenue | 507.63K | 753.53K | 547.88K | 398.61K | 300.84K | 209.30K | 160.63K | 94.40K | 49.41K | 20.06K | 44.44K | 61.12K | 10.99K |
| Gross Profit | 4.05M | 5.74M | 5.05M | 2.66M | 1.40M | 755.23K | 409.22K | 90.48K | 98.22K | 29.14K | 38.53K | 26.03K | 7.09K |
| Gross Profit Ratio | 88.86% | 88.39% | 90.21% | 86.96% | 82.33% | 78.30% | 71.81% | 48.94% | 66.53% | 59.23% | 46.44% | 29.87% | 39.19% |
| Research & Development | 922.70K | 791.33K | 1.12M | 233.53K | 54.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 10.82M | 14.58M | 17.79M | 15.10M | 3.18M | 4.25M | 9.05M | 1.13M | 861.10K | 94.96K | 70.70K | 38.37K | 18.81K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.82M | 14.58M | 17.79M | 15.10M | 3.18M | 4.25M | 9.05M | 1.13M | 861.10K | 94.96K | 70.70K | 38.37K | 18.81K |
| Other Expenses | -28.92K | 344.66K | 25.48K | 32.72K | 84.79K | 21.42K | 9.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.82M | 14.58M | 17.79M | 15.10M | 3.18M | 4.25M | 9.05M | 1.13M | 861.10K | 94.96K | 70.70K | 38.37K | 18.81K |
| Cost & Expenses | 11.33M | 15.33M | 18.34M | 15.49M | 3.48M | 4.45M | 9.21M | 1.23M | 910.51K | 115.02K | 115.14K | 99.49K | 29.80K |
| Interest Income | 0.00 | 398.26K | 37.93K | 177.74K | 46.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 431.42K | 398.26K | 37.93K | 177.74K | 46.60K | 228.33K | 576.02K | 12.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 486.35K | 677.17K | 78.18K | 69.49K | 99.59K | 7.84K | 19.32K | 345.00 | 86.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -6.31M | -8.17M | -12.67M | -12.37M | -1.68M | -3.46M | -8.61M | -1.04M | -762.80K | -65.82K | -32.18K | -12.34K | -11.73K |
| EBITDA Ratio | -138.42% | -125.80% | -226.28% | -404.76% | -98.51% | -358.81% | -1,511.49% | -564.13% | -516.70% | -133.78% | -38.78% | -14.16% | -64.85% |
| Operating Income | -6.77M | -8.84M | -12.74M | -12.44M | -1.78M | -3.49M | -8.64M | -1.04M | -762.88K | -65.82K | -32.18K | -12.34K | -11.73K |
| Operating Income Ratio | -148.45% | -136.23% | -227.68% | -407.03% | -104.36% | -361.85% | -1,516.47% | -564.32% | -516.76% | -133.78% | -38.78% | -14.16% | -64.85% |
| Total Other Income/Expenses | -219.73K | -53.60K | -12.46K | -145.03K | 38.19K | 58.70K | -471.00K | -12.73K | 787.41K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -6.99M | -8.90M | -12.76M | -12.58M | -1.74M | -3.43M | -9.11M | -1.06M | -762.88K | -65.82K | -32.18K | -12.34K | -11.73K |
| Income Before Tax Ratio | -153.28% | -137.06% | -227.90% | -411.78% | -102.12% | -355.76% | -1,599.12% | -571.20% | -516.76% | -133.78% | -38.78% | -14.16% | -64.85% |
| Income Tax Expense | 402.51K | 53.60K | 63.41K | 210.46K | 130.41K | -234.86K | -236.36K | 197.16K | -24.53K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -6.99M | -8.95M | -12.82M | -12.79M | -1.87M | -3.46M | -8.97M | -1.25M | -738.35K | -65.82K | -32.18K | -12.34K | -11.73K |
| Net Income Ratio | -153.28% | -137.89% | -229.03% | -418.66% | -109.78% | -358.95% | -1,574.49% | -677.84% | -500.14% | -133.78% | -38.78% | -14.16% | -64.85% |
| EPS | -0.99 | -1.57 | -2.42 | -3.81 | -0.80 | -2.55 | -16.00 | -2.00 | -2.00 | -2.00 | -0.04 | 0.00 | -0.11 |
| EPS Diluted | -0.99 | -1.57 | -2.42 | -3.81 | -0.80 | -2.55 | -16.00 | -2.00 | -2.00 | -2.00 | -0.04 | 0.00 | -0.11 |
| Weighted Avg Shares Out | 7.03M | 5.69M | 5.30M | 3.35M | 2.33M | 1.36M | 542.98K | 501.89K | 670.24K | 750.60K | 717.26K | 675.00K | 140.53K |
| Weighted Avg Shares Out (Dil) | 7.03M | 5.69M | 5.30M | 3.35M | 2.33M | 1.36M | 542.98K | 501.89K | 670.24K | 750.60K | 717.26K | 675.00K | 140.53K |
RETRANSMISSION: Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
Organicell Announces 1-for-200 Reverse Stock Split
Organicell Reports Interim Results of Phase 1/2A Research Program
Source: https://incomestatements.info
Category: Stock Reports